Jeff Frelick - 15 Jan 2025 Form 4 Insider Report for Bone Biologics Corp (BBLG)

Role
Chief Executive Officer
Signature
/s/ Jeff Frelick
Issuer symbol
BBLG
Transactions as of
15 Jan 2025
Net transactions value
$0
Form type
4
Filing time
21 Jan 2025, 06:10:12 UTC
Previous filing
19 Jan 2024
Next filing
21 Jan 2026
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding BBLG Common Stock 2,151 15 Jan 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BBLG Employee Stock Option Award $0 +54,110 $0.000000 54,110 15 Jan 2025 Common Stock 54,110 $0.9678 Direct F1
holding BBLG Employee Stock Option 25,000 15 Jan 2025 Common Stock 25,000 $3.61 Direct F2
holding BBLG Employee Stock Option 173 15 Jan 2025 Common Stock 173 $9540.00 Direct F2
holding BBLG Employee Stock Option 44 15 Jan 2025 Common Stock 44 $12300.00 Direct F2
holding BBLG Employee Stock Option 157 15 Jan 2025 Common Stock 157 $57.60 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice,vests and becomes exercisable immediately.
F2 This option is fully vested as of the date of this report.